Pulmonary fibrosis is a common complication in various rheumatic immune diseases, and the incidence of pulmonary fibrosis due to systemic scleroderma may exceed 90% and can be considered almost certain. Let’s learn more about how to deal with this complication. Scleroderma can lead to bacterial and viral attacks on the organs of the lungs. After the lungs are attacked, the lung fibroblasts secrete collagen to repair the interstitial lung tissue, which can change the lung decomposition and form fibrosis. Pulmonary fibrosis can bring serious sequelae to patients, and because of its obvious symptoms, diagnosis is relatively easy. 1. Difficulty in breathing is one of the most obvious features. As the collagen encroaches on the original space in the lungs, a significant decrease in lung capacity occurs, and the amount of air entering the lungs with each breath decreases, causing difficulty in breathing. Mild fibrosis only occurs during strenuous activity, but if it occurs at rest, fibrosis in the lungs is more severe. 2. Obstructed breathing. It may lead to chest tightness, weakness, and cyanosis of the hands and feet of the patient. These are caused by the lack of oxygen in the body. 3. Cough and irritating dry cough are also obvious symptoms. Patients with incessant coughing in the absence of other medical conditions and with thick and sometimes bloody sputum are suggestive of fibrosis of the lungs. Fibrosis in the lungs is usually insidious, and patients do not feel it at first, but as time goes on, the condition gradually worsens. If left untreated, the patient may eventually die of heart and lung failure. In addition, fibrosis in the lungs affects the respiratory tract, digestive tract, circulatory system, excretory system, and nervous system, and can lead to serious complications in other areas. Fibrosis of the lungs itself can eventually lead to respiratory failure in patients. It must be clear that there is no specific treatment for pulmonary fibrosis in the medical community, and the mainstream treatment is currently using immunosuppressive drugs and glucocorticoids to assist each other. However, since immunosuppressants can lead to a decrease in one’s immunity and may even lead to cancer attacks, while hormones can lead to osteoporosis and aggravate infections, the side effects are obvious and serious, and are difficult for the average patient to accept. Domestic statistics show that the prognosis of this disease is poor, with a 5-year survival rate of less than 50%. Therefore, patients and their families should be prepared to actively deal with it and take the initiative to prevent it. There are many causes of pulmonary fibrosis, and today we are only talking about pulmonary fibrosis caused by scleroderma. Scleroderma itself is also a relatively insidious disease. The patient usually develops Raynaud’s phenomenon at the initial stage, i.e., the patient’s hands and feet become cold and white after low temperature or mental stimulation, then become blue and purple, and finally return to their original state, accompanied by pain, numbness and other reactions. Raynaud’s phenomenon can generally heal naturally after a period of time, but if a patient develops Raynaud’s phenomenon, it indicates the possibility of a large-scale more serious scleroderma, which must be taken seriously by patients and their families. Early prevention of scleroderma will facilitate its healing and will greatly reduce the likelihood of developing pulmonary fibrosis.